Trial Profile
A Canadian real-world study to evluate the efficacy and safety of ENTYVIO in biologic-naive, adult patients with Ulcerative colitis (UC) or Crohn's disease (CD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Evolve
- 26 Oct 2022 Results (n=362) assessing Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naive Patients With Crohns Disease presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 19 May 2020 Results assessing clinical effectiveness and safety outcomes in patients with UC or CD treated with first-line biologic VDZ as monotherapy or combo therapy with IMMs or 5-ASAs (UC only) published at the Digestive Disease Week 2020
- 19 May 2020 Results (N=218) published in Gasteroenterology in conjunction with Digestive Disease Week 2020